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Abstract
Background: Risk factors for embolism and recurrence of primary cardiac myxoma are not well established. This
study aimed to assess the risk factors for embolism and recurrence of cardiac myxoma, as well as the survival of
the patients.
Methods: The medical records of 207 consecutive patients treated for primary cardiac myxoma between
September 1988 and October 2014 were retrospectively analyzed. All diagnoses were pathologically confirmed.
Data were collected to identify the risk factors influencing the prognosis.
Results: Mean age at surgery was 44.2 ± 15.8 years. Operative mortality (within 30 days of the surgery) occurred in
seven patients. Mean follow-up was 9.35 ± 6.55 years. Embolism occurred in 32 (15.5 %) patients before surgery.
Multivariate analysis indicated that small (≤4.5 cm) myxoma (OR = 5.14; 95 % CI, 2.30–11.94; P < 0.0001) and soft,
gelatinous myxoma (OR = 5.84; 95 % CI, 1.91–25.61; P = 0.001) were independently associated with the occurrence
of embolism. Ten patients experienced recurrences. After excluding the patients who died within 30 days of
surgery, survival was 92.7 % at 10 years. Age, sex, tumor size, cardiopulmonary bypass duration, aortic cross clamp
duration, tumor appearance, and pre-operative embolism were not associated with early mortality. Multivariate
analysis showed that multicentric myxomas were independently associated with recurrence (OR = 9.45, 95 % CI,
2.15–41.3, P = 0.004).
Conclusions: The surgical resection of primary cardiac myxoma is associated with excellent long-term survival.
Tumors ≤4.5 cm and soft tumors were independent risk factors for embolism. Multicentric cardiac myxoma was an
independent risk factors for recurrence of myxoma.
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Background
Primary cardiac tumors are rare and have an estimated
incidence of 0.5–1.0 cases per 1,000,000 people per year
[1]. Primary cardiac myxoma (CM) are the most preva-
lent type of primary cardiac tumors in adults, represent-
ing up to 50–85 % of all benign lesions, while during
fetal development, infancy, and childhood, CMs repre-
sent only 15 % of cardiac tumors with most of them
found in older children [1]. Myxomas most commonly
occur between the third and the sixth decade of life and
tend to be more common in women [2]. CMs most fre-
quently (60–80 %) affect the left atrium [3, 4].
CMs may cause symptoms either because of intracar-
diac obstruction, systemic embolism of tumor fragments,
or constitutional symptoms by unclear mechanisms [2].
The most feared consequences of cardiac myxomas are
preoperative systemic embolism and myxoma recurrence
after surgical resection. However, because of the low in-
cidence of primary cardiac myxoma, only few studies
have analyzed the risk factors associated with embolism
and recurrence of myxomas [5, 6], and there is still a
huge need for more clinically relevant data.
Nevertheless, because of their strategic localization
and inherent histopathological characteristics, CMs are
clinically considered as being malignant entities with
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very serious consequences in terms of morbidity and
mortality. Embolic stroke and heart failure are two sig-
nificant causes of mortality in patients with CM [1], but
the exact factors associated with the occurrence of em-
bolism, early death, or long-term survival are poorly
known.
Therefore, the aim of this study was to assess the risk
factors for embolism and recurrence of CM, as well as
survival of the patients diagnosed with CM between
1988 and 2014 at a single center.
Methods
Study design
This was a retrospective study that was carried out at
the Department of Cardiovascular Surgery of the Provin-
cial Hospital Affiliated to Shandong University, Jinan,
China. This study was approved by the hospital’s Institu-
tional Review Board. Individual consent was waived by
the committee because of the retrospective nature of the
study.
Patients
Patients were included if they had been diagnosed with
and treated for CM between September 1988 and Octo-
ber 2014. Patients were excluded if they had non-
myxomatous cardiac tumors or if they had a malignant
cardiac tumor. Therefore, during this period, 226 pa-
tients with cardiac tumor underwent surgery at our hos-
pital including 6 patients with non-myxomatous benign
tumors and 13 patients with of primary malignant car-
diac tumors, which were excluded. Finally, 207 patients
with CM were included (Fig. 1).
Diagnostic procedures
All patients underwent transthoracic echocardiography
and/or transesophageal echocardiography for preopera-
tive diagnosis. Coronary angiography was indicated to
investigate coronary artery disease in patients >50 years
in order to perform the appropriate coronary treatment
at the same time, if needed. Stroke, transient ischemic
attack, or other systemic/pulmonary embolic event were
diagnosed by magnetic resonance imaging (MRI) or
computed tomography (CT) scan. The patients who ex-
perienced stroke, transient ischemic attacks, cardiac em-
bolism, or any systemic/pulmonary embolic events were
classified as being with pre-operative embolism. CM
diagnosis was confirmed by histopathological assessment
of surgical specimens.
Surgery
Surgical resection of intracardiac CM was performed in
all patients through median sternotomy accompanied by
moderate hypothermia and cardiopulmonary bypass [7].
Myocardial protection was performed by antegrade
blood cardioplegia or crystalloid cardioplegia. The surgi-
cal approach to CM included right atriotomy and trans-
septal route in 190 (91.8 %) patients, right atriotomy in
16 (7.7 %) patients, and pulmonary arteriotomy in one
(0.5 %) patient.
In 134 (64.7 %) patients, the CM resection was ex-
tended to the tumor implantation base, requiring partial
resection of the interatrial septum followed by recon-
struction using a Dacron or autologous pericardial
patch. In two patients with a right atrial CM, the CM
was excised on beating heart during cardiopulmonary
bypass. The duration of cardiopulmonary bypass was
calculated using the data of the patients. The aortic
Fig. 1 Patient flow chart. The diagram shows patient distribution from enrolment to subgrouping of the included study subjects. Of the 7 cases
with multicentric cardiac myxoma, 5 and 2 underwent right atriotomy and transseptal route and right atriotomy, respectively
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cross-clamp time was estimated according to the overall
data of all patients with cardiac arrest.
In order to reduce the risk of local tumor recurrence,
resection lines were coagulated with electrocautery.
After careful inspection, copious irrigation of atria and
ventricles with saline solution was performed to elimin-
ate any tumor fragments.
Concomitant procedures included: mitral valve repair
in three patients, ventricular septal defect repair in two
patients, atrial septal defect repair in one patient, ab-
dominal artery thrombectomy in one patient, amputa-
tion of a lower extremity in one patient, tricuspid valve
repair in four patients, and coronary artery bypass graft-
ing in two patients.
During the study period, all surgeries were performed
by a total of five surgeons who were experienced in car-
diac surgery and had titles of deputy director or above.
They had at least 26 years of experience.
Follow-up
Routine follow-up was performed at 3, 6, and 12 months,
and then yearly; after 4 years, follow-up was performed
if needed or during a routine check-up. Follow-up data
were obtained from subsequent clinical visits, question-
naires mailed to the patients or their family, and/or tele-
phone. Sixteen patients (7.7 %) were lost to follow-up.
The last follow-up recorder for this study was in March
2015.
Data collection
Demographics, disease characteristics, surgery details,
and follow-up information were retrieved from the med-
ical charts. Follow-up included patient survival status,
cardiac function (New York Heart Association (NYHA)
classification), and CM recurrence. The cause of death
was recorded.
Characteristics of the tumors
As per the subsequent receiver operating characteristic
(ROC) curve analysis, a tumor ≤4.5 cm in its largest di-
mension was defined as small CM. Multicentric CM was
defined as a CM occurring in multiple heart chambers
or originated from different parts of a single cardiac cav-
ity. CMs were divided into solid and encapsulated or soft
and gelatinous based on the classification system by Ha
et al. [8]. Tumors with smooth regular borders were
classified as solid, which was characterized by a round
shape and a non-mobile surface. The gelatinous CMs
were characterized by a soft and irregular shape and a
mobile surface. The gelatinous tumors were more fri-
able, often with a cauliflower appearance necessitating
piecemeal removal [9].
Outcomes
The primary outcomes included death from any cause,
heart-related death, CM recurrence, and NYHA status
during follow-up. Heart-related death was defined as an
occurrence of death due to congestive heart failure or
myocardial infarction. CM recurrence was defined as the
recurrence of CM after resection.
Statistical analysis
All statistical analyses were performed with SPSS 17.0
(IBM, Armonk, NY, USA). Continuous variables are pre-
sented as mean ± standard deviation and were analyzed
with Student t tests. Continuous data are presented as
proportions and were analyzed using the chi-square test.
The analyses were performed in two steps. First, analyses
were performed to assess the factors associated with em-
bolism. Then, analyses were carried out to analyze the
factors associated with long-term survival. Univariate
analyses were first performed; then, variables with uni-
variate P-values <0.05 were included in multivariate lo-
gistic regression models. Primary survival analyses were
performed with the Kaplan-Meier method and the log-
rank test. Cox regression models were used to identify
univariate and multivariate predictors of recurrence.
Two-sided P-values <0.05 were considered significant.
Results
Baseline characteristics
Table 1 presents the characteristics of the patients. They
were aged 44.2 ± 15.8 years at diagnosis, 65.7 % were fe-
male, and 78.5 % were pre-operative NYHA class I/II.
The most common symptoms were dyspnea (n = 130,
62.8 %), palpitation (n = 117, 56.5 %), easy fatigability (n
= 49, 23.7 %), and fever (n = 17, 8.2 %). Thirty-two pa-
tients (15.5 %) presented with syncope (n = 21) and
thromboembolism, including cerebral embolism (n = 20,
9.7 %), transient ischemic attack (n = 4), renal arterial
embolism (n = 1), coronary obstruction (n = 1), periph-
eral embolism (n = 5), and aorta embolism (n = 1). Thir-
teen patients (6.3 %) were asymptomatic and their CM
was an incidental finding. None of the patients had a
family history of myxoma nor presented a Carney com-
plex syndrome.
Table 2 presents the characteristics of the patients ac-
cording to CM location. One hundred and seventy-nine
(86.5 %) patients had CM in the left atrium, 12 (5.8 %)
patients had CM in the right atrium, and seven (3.38 %)
had a multicentric disease. One hundred-sixty-seven CM
originated from the interatrial septum at the fossa ovalis.
The tumor size was between 1.0 and 9.4 cm (mean:
5.4 ± 1.8 cm). Solid and encapsulated CMs were ob-
served in 67 (32.4 %) patients and soft and gelatinous
CMs were observed in 140 (67.6 %) patients.
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Preoperative embolic events
Table 3 presents the characteristics of the patients ac-
cording to the presence of pre-operative embolic events.
Of the 207 patients with primary CM treated surgically
at our institution, 32 (15.5 %) presented in the context
of a recent embolic event and met the inclusion criteria:
four were with transient ischemic attacks, 28 with stroke
and other systemic/pulmonary embolic events before
operation. Of the 20 patients with stroke, 12 (60 %) pa-
tients suffered from left stroke, 5 (25 %) had right stroke,
and 3 (15 %) had multiple strokes. Of the eight patients
who experienced a systemic embolic event, five (62.5 %)
had an ischemic event in the extremities, one (12.5 %) in
the renal artery, one (12.5 %) in the coronary circulation,
and one (12.5 %) in the abdominal aorta.
Smaller tumors (4.5 ± 1.7 vs. 5.6 ± 1.7, P = 0.001) and a
gelatinous tumor appearance (P = 0.002) were associated
with the presence of pre-operative embolism, while age,
gender, tumor location, and pre-operative NYHA status
were not (P > 0.05).
In order to evaluate the influence of tumor size on
embolism and to determine the best cut-off point for
subsequent analyses, a ROC curve analysis (Fig. 2) was
carried out. The area under the curve was 0.808 and the
optimal cut-off value for tumor size was 4.5 cm accord-
ing to the Youden Index, resulting in a sensitivity of
83 %, specificity of 75 %, positive predictive value of
38 %, and negative predictive value of 96 %. Univariate
analyses showed that tumors of ≤4.5 cm were associated
with embolic events compared to tumors >4.5 cm (OR
= 4.96; 95 % CI, 2.25–10.97; P < 0.0001).
Moreover, a multivariate logistic regression model in-
cluding patient demographics, tumor location, tumor
size, and tumor appearance revealed that small tumor,
soft and gelatinous myxomas were the most significant
predictors in the occurrence of embolism (Table 4).
Complications
During the first 3 months after surgery, one patient suf-
fered from excessive postoperative hemorrhage. One pa-
tient required tracheostomy for acute respiratory distress
syndrome. One patient required permanent pacemaker
implantation for grade III atrioventricular block. Five pa-
tients showed low cardiac output syndrome. Two pa-
tients showed acute renal failure and needed continuous
renal replacement therapy. Two patients suffered from
postoperative myocardial infarction. Supraventricular
Table 1 Characteristics of the patients
Variables Values
















CPB time (min) 54.7 ± 25.1







LA left atrium, RA right atrium, LV left ventricle, RV right ventricle, MV mitral
valve, TV tricuspid valve, PV pulmonary valve, IAS Interatrial
septum, Multi = multicentric
Table 2 Characteristics of the cardiac myxomas according to tumor location
Origin Age (years) Sex, Female (n) IAS involvement (n) Embolism (n) Appearance Gelatinous (n) Total, n (%)
LA 46.4 118 158 25 121 179 (86.5 %)
RA 37.1 10 3 2 7 12 (5.8 %)
LV 14.4 1 0 1 2 3 (1.45 %)
RV 18 0 0 0 0 1 (0.48 %)
MV 45.7 2 0 1 2 3 (1.45 %)
TV 7 0 0 0 1 1 (0.48 %)
PV 0.83 0 0 0 1 1 (0.48 %)
Multi 21.6 5 6 3 6 7 (3.38 %)
LA left atrium, RA right atrium, LV left ventricle, RV right ventricle, MV mitral valve, TV tricuspid valve, PV pulmonary valve, IAS Interatrial septum, Multi Multicentric
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tachycardia, pneumothorax, pneumonia, cerebral infarc-
tion, and delirium were seen in one patient, respectively.
Early mortality
Seven patients died before hospital discharge, and the
30-day operative mortality was 3.4 %. The causes of early
postoperative mortality were low cardiac output syn-
drome in three patients, acute renal failure in two pa-
tients (one of them died after giving up bedside
hemofiltration due to economic hardship, while the
other succumbed to co-morbidity of severe pulmonary
infection), and postoperative myocardial infarction in
two patients.
A multivariate logistic regression logistic regression
analysis showed that heart function before surgery
(NYHA class III/IV, OR = 6.24, 95 % CI, 1.26–34.5; P =
0.026) and age (OR = 1.08, 95 % CI, 1.02–1.17; P = 0.009)
were associated with early postoperative mortality. Sex,
tumor size, cardiopulmonary bypass duration, aortic
cross clamp duration, tumor appearance, and pre-
operative embolism were not associated with early
mortality.
Recurrences
Follow-up details were available for 184 (92 %) patients
who survived the first month after surgery. Mean follow-
up time was 9.35 ± 6.55 years. During follow-up, ten pa-
tients had a recurrence diagnosed 1 to 15 years (mean of
4.8 ± 4.4 years) after their primary operation (Table 5).
Among these 10 patients, seven had a recurrence in the
first 4 years after surgery. The rates of freedom from re-
currence at 5, 10, 15, and 20 years were 95.5 %, 93.5 %,
92.4 %, and 91.6 % (Fig. 3). Interestingly, 3 recurrent
cases were observed among the 7 cases of multicentric
cardiac myxoma, indicating a recurrence rate of 42.3 %.
Multivariate analysis showed that multicentric myxomas
were independently associated with recurrence (OR =
9.45, 95 % CI 2.15–41.3, P = 0.004)
Long-term survival
There were seven deaths (3.5 %) during follow-up: three
patients died from non-cardiac malignant tumors, one
from upper gastrointestinal bleeding, one from a traffic
accident, and two from heart-related causes (one from
myocardial infarction and another from heart failure).
No death could be directly associated with CM. The sur-
vival was 94.3 %, 92.7 %, and 91.5 % at 5, 10, and
15 years, respectively (Fig. 4).
Multivariate analysis demonstrated that older age at op-
eration was the only significant predictor of mortality
(HR = 1.09, 95 % CI: 1.04–1.15, P = 0.001). There was no
significant difference in survival when patients were strati-
fied by sex (female, HR = 1.67; 95 % CI: 0.495–5.523, P =
0.441), tumor size (HR = 1.00; 95 % CI: 0.73–1.38, P =
0.645), and tumor appearance (HR = 2.22, 95 % CI: 0.69–
7.17, P = 0.158).
Discussion
The aim of this study was to assess the risk factors for
embolism and recurrence of CM, as well as survival of
Table 3 Characteristics of the patients according to the presence of pre-operative embolism
Variables Embolism (n = 32) No embolism (n = 175) P
Age (years) 39.7 ± 16.6 45.0 ± 15.5 0.079
Gender (male) 12 (37.5 %) 59 (33.7 %) 0.689
Location (left atrium) 26 (81.3 %) 154 (88.0 %) 0.389
Appearance (gelatinous) 29 (90.6 %) 111 (63.4 %) 0.002
Size (cm) 4.45 ± 1.66 5.60 ± 1.72 0.001
Preoperative NYHA Status 0.217
I-II 29 (90.6 %) 139 (79.4 %)
III-IV 3 (9.4 %) 36 (20.6 %)
Fig. 2 Receiver operating characteristic curve for embolism. The area
under the curve was 0.808
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the patients. Results showed that embolism occurred in
32 (15.5 %) patients before surgery. Multivariate analysis
indicated that Small (≤4.5 cm) CM and soft, gelatinous
CM were independently associated with the occurrence
of embolism. After excluding the patients who died
within 30 days of surgery, survival was 92.7 % at 10 years.
Multivariate analysis showed that multicentric myxomas
were independently associated with recurrence.
Previous reports have estimated that the risk of embol-
ism associated with CM ranged from 30 to 40 %, and
that >50 % of embolic events affected the central ner-
vous system and retinal arteries [3]. Another study
showed that about 13 % of patients experienced CM re-
currence, mostly in the first 4 years [10]. This study
showed that the overall rates of tumor embolism and re-
currence were 15.5 and 5 %, respectively.
CMs represent the most common type of primary car-
diac tumors. Due to their strategic localization and inher-
ent histopathological characteristics, they are clinically
considered as malignant entities with very serious conse-
quences in terms of morbidity and mortality. The cells
giving rise to CM are considered to be multipotent mes-
enchymal cells, which persist as embryonal residues dur-
ing septation of the heart and differentiate into endothelial
cells, smooth-muscle cells, angioblasts, fibroblasts, cartil-
age cells, and myoblasts [3]. They usually are attached to
the interatrial septum at the border of the fossa ovalis
area, and 75–80 % of CMs occur in the left atrium [3, 11],
which is consistent with this study.
Embolism is a well-known complication of CM. Em-
bolic manifestations have been observed in 30–50 % of
patients with CM. They are caused by tissue fragmenta-
tion, detachment of tumor, and/or dissemination of
overlaying thrombi or foci from the tumor surface.
Therefore, the American Heart Association guidelines
propose that during evaluation of an embolic event, in-
tracardiac masses should be suspected and appropriately
pursued with echocardiography based on a suspicious
clinical presentation [12]. Due to the prevailing left-
sided location of CMs and high pressure within the left
ventricle during systole, systemic embolisms (cerebral
and peripheral) are most frequently encountered in cere-
bral and retinal arteries, followed by arteries of the lower
extremities, visceral, renal and coronary arteries, and
sometimes even in the abdominal aorta [13]. He et al.
think that tumor location, macroscopic appearance,
mean platelet volume, and high platelet count are strong
risk factors for embolic events in patients with cardiac
myxomas [14]. Elbardissi et al. [5] have suggested that
patients with small tumors, minimal symptoms, and no
evidence of mitral regurgitation have a high risk of em-
bolism. This study confirmed these observations and the
results are consistent with reported values [15, 16].
Although coronary embolism is extremely rare, it
should be considered even in patients with no cardiac
risk factors [17, 18]. One of the patients of this present
study had a left atrial myxoma and had no cardiac risk
factors, but she suffered from acute angina and pre-
sented with inferior myocardial infarction secondary to
tumor embolism.
Since Gerbode et al. [19] first described CM recur-
rence, there have been a number of reports describing
patients with multiple recurrences occurring predomin-
ately in patients with CM. The cumulative incidence of
CM recurrence is about 1 to 3 % in sporadic forms,
12 % in familial forms, and 22 % in complex forms [20].
Table 4 Logistic regression model for the risk of embolism
Variable Odds ratio 95 % CI P
Tumor size (≤4.5 cm vs. >4.5 cm) 5.138 2.303–11.936 <0.0001
Soft gelatinous myxoma vs. firm capsulated 5.844 1.910–25.613 0.001
Table 5 Tumor recurrence characteristics in the 10 patients with recurrence
No. Sex Age at onset Primary tumor site Recurrence time (years) Recurrent site
1 F 32 LA 4 LA
2 M 25 LA 10 LA
3 F 33 LA 1 LA
4 F 21 LA 1 LA
5 F 10 LA,RA 4 LA,LV,RV
6 M 54 LA 15 LA
7 F 11 LA 3 LA
8 F 13 LA,RA 2 LA
9 F 37 LA 7 RV
10 F 22 LA,LV 1.5 RA
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This study reported an overall rate of myxoma recur-
rence of 5 %. About 70 % of the recurrences happened
in the first 4 years after operation, but two recurrences
happened at 10 and 15 years after the first resection.
The relationship between local intracardiac recurrence
and the adequacy of surgical resection is quite contro-
versial. It appears that recurrent tumors often do not
recur at the site of the original lesion even in patients in
which a complete excision could not be done. Further-
more, a large series of postsurgical follow-up reported
no recurrent tumors [21]. Shinfeld et al. [22] and
McCarthy et al. [23] have suggested that an inadequate
resection is the most common cause for recurrent CM
arising from the atrial septum. Therefore, resection of
full thickness wall with the tumor should be performed
with good safety margins whenever possible. Jones et al.
suggested the following principles to minimize recur-
rences [24]: 1) minimal manipulation of the tumor; 2)
adequate exposure for complete resection of the tumor;
and 3) inspection of all four heart chambers. Gosev et al.
[1] indicated that the biological characteristics of CM
might be the most reliable factors for recurrence predic-
tion, rather than their overall histopathological presenta-
tion. Shah thinks that younger age at surgery, smaller
tumor dimension and tumor localized to the ventricles
were predictors of recurrence [25].
In this study, all patients had a complete excision, and
only the growth characteristics (multifocal vs. single
mass) were associated with recurrence. Moreover, the re-
sults showed that there were no age differences in pa-
tients with or without embolism, which is inconsistent
with a previous study [5]. Unfortunately, no DNA testing
was performed in this study.
Previous studies have reported a short-term mortality
rate of 3.2 % and overall 10-year survival of 96.8–98 %
[9, 26], which is consistent with this study. In this study,
early death occurred in 3.4 % of patients and only 28.6 %
of late deaths were attributed to heart diseases.
This study is not without limitations. Since this study
was retrospective, the analysis was subjected to multiple
potential biases, and the patients did not have scheduled
follow-up echocardiograms. In addition, not all patients
were follow-up for 10 years, and we had to rely on the
actuarial 10-year survival. Furthermore, the time span of
the study period was large, and we cannot exclude a bias
due to evolving surgical and patient care technologies.
In spite of these limitations, the present retrospective
analysis could provide some valuable information on
CM.
Conclusions
In conclusion, embolism and recurrence are the two fea-
tures that could affect the outcomes of patients with
CM. Due to the risk of embolism, surgery should be per-
formed as soon as possible after diagnosis, especially in
patients with tumor ≤ 4.5 cm. Multicentric growth is a
risk factor for recurrence, which mostly occur in the first
4 years after resection.
Ethics approval and consent to participate
This study was approved by the Provincial Hospital Af-
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Fig. 3 Cumulative incidence of tumor recurrence
Fig. 4 Kaplan-Meier estimate of the survival of patients after surgical
resection of their cardiac myxoma
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